Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Year: 2014
Type: conference-abstract
Source: Cancer Research
Authors: John W. Park, Minetta C. Liu, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Fraser Symmans, Meredith B. Buxton, A. Jo Chien, Amy Wallace, Michelle Melisko, Richard Schwab, Judy Boughey, Debashish Tripathy, Hank Kaplan, Rita Nanda, Stephen Chui, Kathy S. Albain, Stacy Moulder, Anthony Elias, Julie E. Lang, Kirsten Edminston, Donald Northfelt, David Euhus, Qamar Khan, Julia Lyandres, Sarah E. Davis, Christina Yau, Ashish Sanil, Laura J. Esserman, Donald A. Berry
Institutions: University of California, San Francisco, Mayo Clinic, University of Minnesota, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, University of California San Diego, University of Southern California, Swedish Medical Center, University of Chicago, Oregon Health & Science University, Loyola University Chicago, University of Denver, Inova Fairfax Hospital, Mayo Clinic in Arizona, The University of Texas Southwestern Medical Center, University of Kansas, Berry Consultants, LLC (United States)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2047563755